Sun Yat-sen Univ. KRAS mRNA G-quadruplex compound Q29

Sun Yat-sen Univ. KRAS mRNA G-quadruplex compound Q29: sourced facts only. name: "Q29 emerged as the most promising compound, showing high affinity for the KRAS rG4 and inhibiting KRAS translation." [PMID:42679165]; target: "Q29 emerged as the most promising compound, showing high affinity for the KRAS rG4 and inhibiting KRAS translation." [PMID:42679165]; developer: "School of Pharmaceutical Sciences, State Key Laboratory of Anti-Infective Drug Discovery and Development, Sun Yat-sen University, Guangzhou510006, China." [PMID:42679165]; stage: "Q29 also exhibited potent antiproliferative activity across KRAS mutant cancer cells, improved cellular uptake and tolerability relative to 15a, and significant antitumor efficacy in a MIA PaCa-2 xenograft model." [PMID:42679165]